Business
Standard BioTools Reports First Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 revenue of $40.8 million45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-yearOperationalized $10 million more in annual run rate cost reductions, totaling $90 million since merger Strong balance sheet with $261 mil
About this update from Standard Biotools Inc.
[{"type":"image","alt":"Standard BioTools Inc.","displaySize":"","headline":null,"caption":"Standard BioTools Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/62bb817180017915a417644b36a1d053"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fFQS13CdQZEX2RHrMp.CBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/62bb817180017915a417644b36a1d053","width":300,"height":214}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the first quarter ended March 31, 2025.","length":220,"tagName":"p"},{"type":"text","content":"Recent Highlights:","length":18,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"First quarter 2025 revenue of $40.8 million","length":43,"tagName":"p"}]},{"val":[{"type":"text","content":"45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-year","length":85,"tagName":"p"}]},{"val":[{"type":"text","content":"Operationalized $10 million more in annual run rate cost reductions, totaling $90 million since merger ","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong balance sheet with $261 million in cash & cash equivalents and no material debt as of March 31, 2025","length":111,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":341,"olType":false},{"type":"text","content":"“Standard BioTools delivered a solid first quarter in line with our expectations, reflecting focused execution in a challenging Life Sciences macro backdrop,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "We remain grounded and disciplined, driving a 29% year-over-year improvement in adjusted EBITDA through Standard BioTools Business System (SBS). We believe our unique model, world class operational platform and healthy capital position will allow us to continue to take advantage of the current environment and deliver shareholder value over time.”","length":599,"tagName":"p"},{"type":"text","content":"Dr. Egholm added, "On a product level, I am particularly excited by our strategic foothold in proteomics and the momentum building f...